Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

HODGKIN LYMPHOMA DIAGNOSED DURING THE SECOND TRIMESTER OF PREGNANCY AND TREATED WITH ABVD CHEMOTHERAPY WITH FAVORABLE MATERNAL AND NEONATAL OUTCOMES: A CASE REPORT.

Created on 16 Aug 2026

Authors

N Ghukasyan, M Melik-Andreasyan, L Sahakyan

Published in

Georgian medical news. Issue 375. Pages 51-54.

Abstract

Hodgkin lymphoma (HL) during pregnancy is rare and presents diagnostic and therapeutic challenges. Optimal management requires balancing maternal oncologic benefit and fetal safety through a multidisciplinary approach.
A 25-year-old Armenian woman presented at 26 weeks' gestation with fatigue, night sweats, and significant weight loss. Magnetic resonance imaging without contrast revealed an anterior mediastinal mass. Histopathology confirmed classical Hodgkin lymphoma, nodular sclerosis subtype. Following multidisciplinary discussion, antenatal chemotherapy with the ABVD regimen was initiated. Two cycles were administered during pregnancy with close maternal and fetal monitoring. Pregnancy progressed uneventfully to 37 weeks, when a planned cesarean section was performed. A healthy male neonate was delivered with good Apgar scores. Postpartum, the mother completed chemotherapy and achieved complete remission.
This case demonstrates that Hodgkin lymphoma diagnosed during the second trimester can be safely treated with ABVD chemotherapy during pregnancy when managed by a multidisciplinary team, resulting in favorable maternal and neonatal outcomes.

PMID:
42603315
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement